Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease

dc.contributor.authorMartinez-Montoro, Jose Ignacio
dc.contributor.authorCornejo-Pareja, Isabel
dc.contributor.authorGomez-Perez, Ana Maria
dc.contributor.authorTinahones, Francisco J.
dc.contributor.authoraffiliation[Martinez-Montoro, Jose Ignacio] Virgen Victoria Univ Hosp, Dept Endocrinol & Nutr, Malaga 29010, Spain
dc.contributor.authoraffiliation[Gomez-Perez, Ana Maria] Virgen Victoria Univ Hosp, Dept Endocrinol & Nutr, Malaga 29010, Spain
dc.contributor.authoraffiliation[Martinez-Montoro, Jose Ignacio] Univ Malaga, Fac Med, Malaga 29071, Spain
dc.contributor.authoraffiliation[Tinahones, Francisco J.] Univ Malaga, Fac Med, Malaga 29071, Spain
dc.contributor.authoraffiliation[Cornejo-Pareja, Isabel] Virgen Victoria Univ Hosp, Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain
dc.contributor.authoraffiliation[Tinahones, Francisco J.] Virgen Victoria Univ Hosp, Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain
dc.contributor.authoraffiliation[Cornejo-Pareja, Isabel] Inst Salud Carlos III, Spanish Biomed Res Ctr Physiopathol Obes & Nutr C, Madrid 28029, Spain
dc.contributor.authoraffiliation[Tinahones, Francisco J.] Inst Salud Carlos III, Spanish Biomed Res Ctr Physiopathol Obes & Nutr C, Madrid 28029, Spain
dc.contributor.funderSpanish Ministry of Economy and Competitiveness (ISCIII)
dc.contributor.funderFondo Europeo de Desarrollo Regional FEDER
dc.contributor.funderServicio Andaluz de Salud
dc.contributor.funder"Centros de Investigacion Biomedica en Red" (CIBER) of the Institute of Health Carlos III (ISCIII)
dc.contributor.funderISCIII
dc.contributor.funderEuropean Regional Development Fund (ERDF)
dc.date.accessioned2025-01-07T15:22:10Z
dc.date.available2025-01-07T15:22:10Z
dc.date.issued2021-11-01
dc.description.abstractIn the last decades, the global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached pandemic proportions with derived major health and socioeconomic consequences; this tendency is expected to be further aggravated in the coming years. Obesity, insulin resistance/type 2 diabetes mellitus, sedentary lifestyle, increased caloric intake and genetic predisposition constitute the main risk factors associated with the development and progression of the disease. Importantly, the interaction between the inherited genetic background and some unhealthy dietary patterns has been postulated to have an essential role in the pathogenesis of NAFLD. Weight loss through lifestyle modifications is considered the cornerstone of the treatment for NAFLD and the inter-individual variability in the response to some dietary approaches may be conditioned by the presence of different single nucleotide polymorphisms. In this review, we summarize the current evidence on the influence of the association between genetic susceptibility and dietary habits in NAFLD pathophysiology, as well as the role of gene polymorphism in the response to lifestyle interventions and the potential interaction between nutritional genomics and other emerging therapies for NAFLD, such as bariatric surgery and several pharmacologic agents.
dc.identifier.doi10.3390/nu13114077
dc.identifier.essn2072-6643
dc.identifier.pmid34836332
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6643/13/11/4077/pdf?version=1636970277
dc.identifier.urihttps://hdl.handle.net/10668/27076
dc.identifier.wosID723718400001
dc.issue.number11
dc.journal.titleNutrients
dc.journal.titleabbreviationNutrients
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.publisherMdpi
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectnon-alcoholic fatty liver disease
dc.subjectgene polymorphism
dc.subjectdietary intervention
dc.subjectgene-nutrient interactions
dc.subjectbariatric surgery
dc.subjectpharmacotherapy
dc.subjectDe-novo lipogenesis
dc.subjectWeight-loss
dc.subjectMetabolic syndrome
dc.subjectPnpla3 p.i148m
dc.subjectOmega-3 supplementation
dc.subjectRs738409 polymorphism
dc.subjectInsulin-resistance
dc.subjectBariatric surgery
dc.subjectOxidative stress
dc.subjectI148m variant
dc.titleImpact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
dc.typereview
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeReview

Files